Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.

Gregor Brecl JakobBarbara BarunSarah GomezeljTereza GabelićSaša Šega JazbecIvan AdamecAlenka Horvat LedinekUroš RotMagdalena Krbot SkorićMario Habek

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)

According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.

Keyphrases

multiple sclerosis
clinical practice
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
white matter
electronic health record
prognostic factors
patient reported outcomes
machine learning
cross sectional
big data
combination therapy
double blind
patient reported
smoking cessation